A detailed history of Rtw Investments, LP transactions in Uni Qure N.V. stock. As of the latest transaction made, Rtw Investments, LP holds 10,000 shares of QURE stock, worth $173,500. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,000
Holding current value
$173,500
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.78 - $10.12 $37,800 - $101,199
10,000 New
10,000 $49,000
Q4 2020

Feb 16, 2021

SELL
$35.35 - $50.67 $5.6 Million - $8.03 Million
-158,479 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$35.98 - $47.66 $43,068 - $57,049
1,197 Added 0.76%
158,479 $5.84 Million
Q2 2020

Aug 14, 2020

BUY
$45.06 - $67.74 $54,342 - $81,694
1,206 Added 0.77%
157,282 $7.09 Million
Q1 2020

May 15, 2020

BUY
$40.01 - $73.97 $159,239 - $294,400
3,980 Added 2.62%
156,076 $7.41 Million
Q4 2019

Feb 14, 2020

BUY
$37.13 - $74.62 $266,853 - $536,293
7,187 Added 4.96%
152,096 $10.9 Million
Q3 2019

Nov 14, 2019

BUY
$39.36 - $76.8 $12,359 - $24,115
314 Added 0.22%
144,909 $5.7 Million
Q2 2019

Aug 14, 2019

SELL
$52.76 - $82.19 $499,267 - $777,763
-9,463 Reduced 6.14%
144,595 $11.3 Million
Q1 2019

May 15, 2019

SELL
$27.39 - $68.41 $8.43 Million - $21.1 Million
-307,779 Reduced 66.64%
154,058 $9.19 Million
Q4 2018

Feb 14, 2019

BUY
$22.8 - $33.93 $749,139 - $1.11 Million
32,857 Added 7.66%
461,837 $13.3 Million
Q3 2018

Nov 14, 2018

BUY
$29.75 - $43.08 $583,397 - $844,798
19,610 Added 4.79%
428,980 $15.6 Million
Q2 2018

Aug 14, 2018

BUY
$21.96 - $39.94 $59,357 - $107,957
2,703 Added 0.66%
409,370 $15.5 Million
Q1 2018

May 14, 2018

BUY
$17.1 - $26.61 $53,745 - $83,635
3,143 Added 0.78%
406,667 $9.56 Million
Q4 2017

Feb 14, 2018

BUY
$9.47 - $19.59 $3.82 Million - $7.91 Million
403,524
403,524 $7.91 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $811M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Rtw Investments, LP Portfolio

Follow Rtw Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rtw Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Rtw Investments, LP with notifications on news.